DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]
This study will compare DS 8201a to standard treatment.
Participants must have HER2 breast cancer that has been treated before.
- cannot be removed by an operation
- has spread to other parts of the body
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY OF TRASTUZUMAB DERUXTECAN (DS-8201A), AN ANTIHER2-ANTIBODY DRUG CONJUGATE, VERSUS TREATMENT OF INVESTIGATOR?S CHOICE FOR HER2-POSITIVE, UNRESECTABLE AND/OR METASTATIC BREAST CANCER SUBJECTS PREVIOUSLY TREATED WITH T-DM1
- ClinicalTrials.gov Identifier: NCT03523585
- Protocol Number: 18-500
- Principal Investigator: Neelam Desai
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required